Advisors Asset Management, Inc. Bei Gene, Ltd. Transaction History

Advisors Asset Management, Inc.

$5.28 Billion
Q3 2024

A detailed history of Advisors Asset Management, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 280 shares of BGNE stock, worth $51,718. This represents 0.0% of its overall portfolio holdings.

Number of Shares

280

Previous 494 43.32%

Holding current value

$51,718

Previous $70,000 11.43%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$143.93 - $224.51 $30,801 - $48,045	-214 Reduced 43.32%	280 $62,000
Q2 2024 Aug 14, 2024	SELL	$129.52 - $174.32 $19,298 - $25,973	-149 Reduced 23.17%	494 $70,000
Q1 2024 May 14, 2024	SELL	$141.8 - $181.47 $30,345 - $38,834	-214 Reduced 24.97%	643 $100,000
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $3,490 - $4,434	-22 Reduced 2.5%	857 $154,000
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $3,209 - $4,802	18 Added 2.09%	879 $156,000
Q1 2023 May 12, 2023	SELL	$215.53 - $274.5 $6,465 - $8,235	-30 Reduced 3.37%	861 $185,000
Q4 2022 Feb 13, 2023	BUY	$125.51 - $229.3 $13,680 - $24,993	109 Added 13.94%	891 $195,000
Q3 2022 Nov 08, 2022	SELL	$131.8 - $202.24 $64,713 - $99,299	-491 Reduced 38.57%	782 $105,000
Q2 2022 Aug 08, 2022	BUY	$121.11 - $216.05 $3,512 - $6,265	29 Added 2.33%	1,273 $206,000
Q1 2022 May 17, 2022	BUY	$146.52 - $269.56 $38,388 - $70,624	262 Added 26.68%	1,244 $235,000
Q4 2021 Feb 15, 2022	BUY	$248.56 - $389.34 $32,809 - $51,392	132 Added 15.53%	982 $266,000
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $51,168 - $82,643	-205 Reduced 19.43%	850 $309,000
Q2 2021 Jul 30, 2021	SELL	$292.75 - $367.01 $192,336 - $241,125	-657 Reduced 38.38%	1,055 $362,000
Q1 2021 May 07, 2021	SELL	$260.64 - $382.12 $45,612 - $66,871	-175 Reduced 9.27%	1,712 $596,000
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $81,884 - $117,145	370 Added 24.39%	1,887 $488,000
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $41,052 - $62,157	217 Added 16.69%	1,517 $435,000
Q2 2020 Aug 12, 2020	BUY	$123.9 - $195.41 $2,354 - $3,712	19 Added 1.48%	1,300 $245,000
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $42,156 - $59,923	346 Added 37.01%	1,281 $158,000
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $75,604 - $136,046	653 Added 231.56%	935 $155,000
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $9,890 - $12,159	82 Added 41.0%	282 $35,000
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $9,119 - $11,748	80 Added 66.67%	200 $25,000
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $14,738 - $18,219	120 New	120 $16,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.2B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.

Account

Advisors Asset Management, Inc. Bei Gene, Ltd. Transaction History